[1]

Berrocal MH, Acaba-Berrocal L, Acaba AM. 2022. Long-term outcomes of same patient eyes treated with pars Plana Vitrectomy in one eye and conventional treatment in the other for complications of proliferative diabetic retinopathy. Journal of Clinical Medicine 11:5399

doi: 10.3390/jcm11185399
[2]

Antonetti DA, Klein R, Gardner TW. 2012. Diabetic retinopathy. New England Journal of Medicine 366:1227−39

doi: 10.1056/nejmra1005073
[3]

Shani M, Eviatar T, Komaneshter D, Vinker S. 2018. Diabetic retinopathy-incidence and risk factors in a community setting- a longitudinal study. Scandinavian Journal of Primary Health Care 36:237−41

doi: 10.1080/02813432.2018.1487524
[4]

American Diabetes Association. 2016. Classification and diagnosis of diabetes. Diabetes Care 39:S13−s22

doi: 10.2337/dc16-S005
[5]

Holekamp NM. 2016. Overview of diabetic macular edema. The American Journal of Managed Care 22:s284−s291
[6]

Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. 2013. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Therapeutic Advances in Endocrinology and Metabolism 4:151−69

doi: 10.1177/2042018813512360
[7]

Ascaso FJ, Huerva V, Grzybowski A. 2014. The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. Mediators of Inflammation 2014:432685

doi: 10.1155/2014/432685
[8]

Munk MR, Somfai GM, de Smet MD, Donati G, Menke MN, et al. 2022. The role of intravitreal corticosteroids in the treatment of DME: predictive OCT biomarkers. International Journal of Molecular Sciences 23:7585

doi: 10.3390/ijms23147585
[9]

Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. 2015. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 314:2137−46

doi: 10.1001/jama.2015.15217
[10]

Berrocal MH, Acaba-Berrocal L. 2021. Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature. Current Opinion in Ophthalmology 32:203−8

doi: 10.1097/ICU.0000000000000760
[11]

Stefánsson E. 2009. Physiology of vitreous surgery. Graefe's Archive for Clinical and Experimental Ophthalmology 247(2):147−163

doi: 10.1007/s00417-008-0980-7
[12]

Lee SS, Ghosn C, Yu Z, Zacharias LC, Kao H, et al. 2010. Vitreous VEGF clearance is increased after vitrectomy. Investigative Ophthalmology & Visual Science 51:2135−38

doi: 10.1167/iovs.09-3582
[13]

Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, et al. 2006. Müller cells in the healthy and diseased retina. Progress in Retinal and Eye Research 25:397−424

doi: 10.1016/j.preteyeres.2006.05.003
[14]

Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, et al. 2018. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmology 136:1138−48

doi: 10.1001/jamaophthalmol.2018.3255
[15]

Cruz-Iñigo YJ, Acabá LA, Berrocal MH. 2014. Surgical management of retinal diseases: proliferative diabetic retinopathy and traction retinal detachment. In Microincision Vitrectomy Surgery: Emerging Techniques and Technology, eds Oh H, Oshima Y. Basel, Switzerland: Karger. Volume 54. pp. 196−203 doi: 10.1159/isbn.978-3-318-02661-0
[16]

Huang CH, Hsieh YT, Yang CM. 2017. Vitrectomy for complications of proliferative diabetic retinopathy in young adults: clinical features and surgical outcomes. Graefe's Archive for Clinical and Experimental Ophthalmology 255:863−71

doi: 10.1007/s00417-016-3579-4
[17]

Yeh PT, Yang CH, Yang CM. 2011. Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy. Acta Ophthalmologica 89:634−40

doi: 10.1111/j.1755-3768.2009.01821.x
[18]

Chen SN, Chen SJ, Wu TT, Wu WC, Yang CH, et al. 2023. Refining vitrectomy for proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 261:3659−70

doi: 10.1007/s00417-023-06134-w
[19]

Huang CH, Yang CM. 2020. Recurrent retinal detachment after diabetic vitrectomy. International Ophthalmology 40:1931−39

doi: 10.1007/s10792-020-01366-9
[20]

Daruich A, Matet A, Moulin A, Kowalczuk L, Nicolas M, et al. 2018. Mechanisms of macular edema: Beyond the surface. Progress in Retinal and Eye Research 63:20−68

doi: 10.1016/j.preteyeres.2017.10.006
[21]

Tang J, Kern TS. 2011. Inflammation in diabetic retinopathy. Progress in Retinal and Eye Research 30:343−58

doi: 10.1016/j.preteyeres.2011.05.002
[22]

Ou WC, Brown DM, Payne JF, Wykoff CC. 2017. Relationship between visual acuity and retinal thickness during anti–vascular endothelial growth factor therapy for retinal diseases. American Journal of Ophthalmology 180:8−17

doi: 10.1016/j.ajo.2017.05.014
[23]

Radwan SH, Soliman AZ, Tokarev J, Zhang L, van Kuijk FJ, et al. 2015. Association of disorganization of retinal inner layers with vision after resolution of center-involved diabetic macular edema. JAMA Ophthalmology 133:820−25

doi: 10.1001/jamaophthalmol.2015.0972
[24]

Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, et al. 2014. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmology 132:1309−16

doi: 10.1001/jamaophthalmol.2014.2350
[25]

Das R, Spence G, Hogg RE, Stevenson M, Chakravarthy U. 2018. Disorganization of inner retina and outer retinal morphology in diabetic macular edema. JAMA Ophthalmology 136:202−8

doi: 10.1001/jamaophthalmol.2017.6256
[26]

Midena E, Torresin T, Velotta E, Pilotto E, Parrozzani R, et al. 2021. OCT hyperreflective retinal foci in diabetic retinopathy: a semi-automatic detection comparative study. Frontiers in Immunology 12:613051

doi: 10.3389/fimmu.2021.613051